E-cadherin promoter polymorphisms are not associated with the aggressiveness of prostate cancer in Caucasian patients

Li, He-Cheng; Albert, Jeffrey M.; Shinohara, Eric T.; Cai, Qiuyin; Freyer, Andrea; Cai, Hui; Cao, Carolyn; Wang, Zuofei; Kataoka, Nobuhiko; Teng, Ming; Zheng, Wei; Lu, Bo

doi:10.1016/j.urolonc.2006.02.018

« Previous Next »Urologic Oncology: Seminars and Original Investigations
Volume 24, Issue 6 , Pages 496-502, November 2006

E-cadherin promoter polymorphisms are not associated with the aggressiveness of prostate cancer in Caucasian patients☆

He-Cheng Li, M.D., Ph.D.
- Vanderbilt University School of Medicine, Nashville, TN 37232, USA
Jeffrey M. Albert, B.S.
- Department of Radiation Oncology and Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
Eric T. Shinohara, M.D.
- Department of Radiation Oncology and Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
Qiuyin Cai, M.D., Ph.D.
- Department of Medicine and Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
Andrea Freyer, B.S.
- Department of Radiation Oncology and Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
Hui Cai, M.D., Ph.D.
- Department of Medicine and Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
Carolyn Cao, M.S.
- Department of Radiation Oncology and Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
Zuofei Wang, M.D.
- Department of Radiation Oncology and Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
Nobuhiko Kataoka, M.D., Ph.D.
- Department of Medicine and Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
Ming Teng, M.D.
- Department of Radiation Oncology and Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
Wei Zheng, M.D., Ph.D.
- Department of Medicine and Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
Bo Lu, M.D., Ph.D.
- Department of Radiation Oncology and Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
- Corresponding author. Tel.: +1-615-343-9233; fax: +1-615-343-0161.

Received 8 September 2005; received in revised form 8 February 2006; accepted 9 February 2006.

Abstract

Background

−160C→A and −347G→GA polymorphisms in the promoter region decrease E-cadherin gene transcription. Decreased E-cadherin expression predicts poor outcome among patients with cancer. We sought to investigate whether −160C→A and/or −347G→GA polymorphisms were associated with the aggressiveness of prostate cancer.

Methods

TaqMan single nucleotide polymorphism genotyping assay (Applied Biosystems, Foster City, CA) was used to detect −160C→A and −347G→GA polymorphisms in deoxyribonucleic acid from the paraffin-embedded prostate tissues of 98 Caucasian patients.

Results

The genotype frequencies were −160C/C: 48% (47 of 98); −160C/A: 44% (43 of 98); −160A/A: 8% (8 of 98); −347G/G: 68% (67 of 98); −347G/GA: 28% (27 of 98); and −347GA/GA: 4% (4 of 98). Using the chi-square test, we found that the polymorphisms −160C→A and −347G→GA were not related to other clinical and pathologic parameters (i.e., age, prostate-specific antigen level, Gleason grade, and clinical stage) (P > 0.05). In combination analysis, there was no significant relationship between patients with both −160C/C and −347G/G, and these same parameters (P > 0.05). Using the log-rank test, we found no significant difference in relapse-free survival and overall survival between patients with −160C/C and those with −160A/C or −160A/A (P = 0.0764 and 0.2746, respectively), and also no significant difference between patients with −347G/G and those with −347GA/G or −347GA/GA (P = 0.9416 and 0.7367, respectively). There was also no significant difference in relapse-free survival and overall survival between patients with homozygosities of −160C/-347G and patients with other genotypes (P = 0.1418 and 0.2434, respectively).

Conclusion

We conclude that E-cadherin −160C→A and/or −347G→GA polymorphisms are not associated with the aggressiveness of prostate cancer in Caucasian patients.

Keywords: Prostate cancer, E-cadherin, Promoter, Polymorphism, Aggressiveness